Mexican analytical testing laboratory seeks European partners; evolve into Mexico-based pharma/biotech CDMO
Mexican authorised analytical testing laboratory seeks European commercial partners and strategic partners for pharmaceutical and biotechnology development
Term of Validity: 17 September 2026 - 17 September 2027
Summary - Profile Type - Business Offer - POD Reference - BOMX20260917002 - Term of Validity - 17 September 2026 - 17 September 2027 - Company’s Country - Mexico - Type of partnership - Commercial agreement - Supplier agreement - Targeted Countries - All countries General information - Short Summary - A Mexican analytical testing laboratory with 10 years of experience offers advanced quality testing, analytical method development and validation services for pharmaceutical raw materials, medicines and medical devices. The company seeks European commercial partners to promote its services and expand its client portfolio, as well as strategic partners interested in supporting its development into a CDMO focused on pharmaceutical and biotechnology projects. - Full Description - The Mexican company is an analytical testing laboratory with 10 years of experience in the pharmaceutical sector, providing services to pharmaceutical companies in Mexico and international markets, including Colombia, Argentina, Peru and the United States. The laboratory provides advanced analytical services for raw materials, pharmaceutical ingredients, medicines and medical devices, following international guidelines and Mexican regulatory requirements. Its analytical capabilities include: - Physicochemical analysis - Chromatography - Microbiology - Molecular biology - Biological testing - Analytical method development and validation - Quality and stability studies - Pharmaceutical formulation development - Filling and final quality testing The company has more than 100 validated analytical methods, including methods referenced in internationally recognised pharmacopoeias such as the USP, European Pharmacopoeia and Mexican Pharmacopoeia. Its technical team can also develop new analytical methods when established methods are not available. The laboratory is authorised by the Mexican health authority COFEPRIS as an authorised third-party laboratory, supporting pharmaceutical registration holders with analytical testing required for the commercialisation of medicines and medical devices in Mexico. It also has qualified facilities for the development of biotechnology medicines at preclinical scale. The company is pursuing two complementary internationalisation objectives. First, it seeks European commercial partners capable of promoting its analytical services and attracting pharmaceutical and medical device clients requiring analytical support in Mexico. Second, it seeks strategic partners and investors interested in supporting its evolution into a CDMO in Mexico for the development of pharmaceutical ingredients and biomedicines up to the preclinical stage. As part of its internationalisation strategy, the company regularly participates in international pharmaceutical and biotechnology events in Europe to develop relationships with potential clients, commercial partners and strategic collaborators. - Advantages and Innovations - - Integrated analytical support, from method development and validation to stability and final quality testing, facilitating continuity throughout the development process. - Regulatory experience in Mexico, supported by its status as a COFEPRIS-authorised third-party laboratory, which can facilitate the analytical pathway for companies seeking access to the Mexican market. - Problem-solving capability for complex analytical requirements, including the development of new methods when standard or previously established methods are not available. - Combination of analytical and preclinical development capabilities, providing a foundation for progressively supporting more complex pharmaceutical and biotechnology projects. - Potential bridge between European innovation and the Mexican pharmaceutical market, combining local regulatory knowledge, existing infrastructure and an established pharmaceutical client base. - The planned evolution towards a CDMO model would allow European partners to participate at an early stage in building complementary development capabilities in Mexico, particularly for pharmaceutical ingredients and biomedicines. - Stage of Development - Already on the market - Sustainable Development Goals - Goal 3: Good Health and Well-being - IPR status - No IPR applied Partner Sought - Expected Role of a Partner - The company is seeking two types of European partners: a) Commercial partners: pharmaceutical and life sciences consultants, business development organisations, specialised commercial representatives or other organisations with access to pharmaceutical and medical device companies. The partner would promote the laboratory’s services, identify potential clients and support the development of a European customer portfolio. b) Strategic partners
investors: pharmaceutical, biotechnology or CDMO companies and investors interested in participating in the development of a CDMO platform in Mexico focused on pharmaceutical ingredients and biomedicines up to preclinical stage. Strategic partners may contribute investment, technical expertise, CDMO experience, market access or complementary capabilities to accelerate the development of the new operation. The Mexican company would contribute its existing analytical infrastructure, regulatory experience, technical capabilities and knowledge of the Mexican pharmaceutical environment. - Type and Size of Partner - Other - SME 11-49 - SME <=10 - University - Big company - R&D Institution - SME 50 - 249 - Type of partnership - Commercial agreement - Supplier agreement Dissemination - Technology keywords - 06001005 - Diagnostics, Diagnosis - Market keywords - 05001002 - In-vitro diagnostics - 04009 - In vitro Testing, Trials - 09003007 - Other services (not elsewhere classified) - Targeted countries - All countries